Suppl. Figure e-1



Figure e-1: CD3⁺ T-lymphocyte Counts in Alemtuzumab-treated Patients With or Without Autoimmune Adverse Events or Disease Activity

Median total CD3⁺ T-lymphocyte counts in CARE-MS patients treated with alemtuzumab 12 mg, stratified by the presence or absence of (A) autoimmune AEs, (B) relapse, (C) 6-month CDW, and (D) MRI disease activity. N value range over 24 months: 415–447 patients without autoimmune AEs; 337–355 patients with autoimmune AEs; 356–388 patients without relapse; 395–414 patients with relapse; 567–606 patients without CDW; 184–196 patients with CDW; 263–280 patients without MRI activity; 485–516 patients with MRI activity. AE = adverse event; CDW = confirmed disability worsening; IQR = interquartile range; LLN = lower limit of normal.